Published in Neuro Oncol on December 13, 2007
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro (2011) 1.44
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia (2014) 1.23
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 1.04
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther (2014) 1.02
Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc Natl Acad Sci U S A (2010) 1.00
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther (2010) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol (2009) 0.95
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol (2008) 0.92
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol (2013) 0.90
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A (2010) 0.86
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia (2012) 0.86
Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev (2013) 0.86
Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum Gene Ther Methods (2012) 0.85
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One (2010) 0.84
Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther (2014) 0.82
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Abundance of Flt3 and its ligand in astrocytic tumors. Onco Targets Ther (2013) 0.75
Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Hum Gene Ther Methods (2016) 0.75
Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business! Mol Ther (2014) 0.75
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Adv Pharmacol (2016) 0.75
Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res (2017) 0.75
The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology (1968) 7.42
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol (2003) 5.28
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther (2001) 2.83
Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther (1999) 2.82
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys (1989) 2.72
Improved system for helper-dependent adenoviral vector production. Mol Ther (2003) 2.71
Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 2.53
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther (2004) 2.32
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 2.26
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther (2004) 2.15
Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol (1983) 2.12
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A (2000) 2.05
Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci (2004) 2.03
Intracranial metastases from systemic cancer. Adv Neurol (1978) 1.92
Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther (1999) 1.84
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol (1988) 1.84
Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol (1999) 1.81
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 1.76
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest (2004) 1.44
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med (1997) 1.35
Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol (2001) 1.34
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther (1994) 1.29
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol (2000) 1.26
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 1.26
Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia (2006) 1.26
Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother (2001) 1.23
The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer (1987) 1.20
Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer (1997) 1.20
The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol (1991) 1.20
Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods (1996) 1.19
Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther (2005) 1.13
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg (1999) 1.12
FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol (1997) 1.12
Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther (1998) 1.07
Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol (1998) 1.07
Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res (2003) 1.07
Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther (2006) 1.02
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther (1996) 1.02
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther (2004) 0.98
Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol (2005) 0.98
Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia (2005) 0.96
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther (2002) 0.94
Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther (2001) 0.94
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther (2000) 0.93
High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods Enzymol (2002) 0.93
FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol (1998) 0.93
Dendritic cell-based glioma immunotherapy (review). Int J Oncol (2003) 0.92
An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther (1997) 0.91
Suicide gene therapy for plasma cell tumors. Blood (1996) 0.90
Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol (1999) 0.89
Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res (1994) 0.88
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther (1996) 0.85
HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Surg (1996) 0.85
Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res (1997) 0.84
Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery (2007) 0.82
Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther (2001) 0.82
Dendritic cells and immune responses in the central nervous system. Trends Immunol (2002) 0.82
MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J Neurooncol (2003) 0.81
Effect of vimentin on reactive gliosis: in vitro and in vivo analysis. J Neurotrauma (2004) 0.81
Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother (2002) 0.78
Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. J Neurosurg (1996) 0.77
Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. Int J Cancer (1991) 0.77
Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther (1995) 0.76
A new rat brain tumor model: glioma disseminated via the cerebral spinal fluid pathways. J Neurooncol (1990) 0.76
Antileukemic activity of Flt3 ligand in murine leukemia. Cancer Res (2000) 0.76
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst (2002) 2.42
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Loss of function of OsDCL1 affects microRNA accumulation and causes developmental defects in rice. Plant Physiol (2005) 1.77
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Brain edema after intracerebral hemorrhage in rats: the role of inflammation. Neurol India (2006) 1.69
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
The relationship of hamstrings and quadriceps strength to anterior cruciate ligament injury in female athletes. Clin J Sport Med (2009) 1.55
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Hysteroscopic surgery of ectopic pregnancy in the cesarean section scar. J Minim Invasive Gynecol (2009) 1.46
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Roles of DCL4 and DCL3b in rice phased small RNA biogenesis. Plant J (2011) 1.42
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
ARGONAUTE10 and ARGONAUTE1 regulate the termination of floral stem cells through two microRNAs in Arabidopsis. PLoS Genet (2011) 1.40
SDG714, a histone H3K9 methyltransferase, is involved in Tos17 DNA methylation and transposition in rice. Plant Cell (2007) 1.39
Arginine methylation mediated by the Arabidopsis homolog of PRMT5 is essential for proper pre-mRNA splicing. Proc Natl Acad Sci U S A (2010) 1.36
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Comparative analysis of JmjC domain-containing proteins reveals the potential histone demethylases in Arabidopsis and rice. J Integr Plant Biol (2008) 1.35
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Oryza sativa dicer-like4 reveals a key role for small interfering RNA silencing in plant development. Plant Cell (2007) 1.30
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Mutations in the Type II protein arginine methyltransferase AtPRMT5 result in pleiotropic developmental defects in Arabidopsis. Plant Physiol (2007) 1.22
AGAMOUS terminates floral stem cell maintenance in Arabidopsis by directly repressing WUSCHEL through recruitment of Polycomb Group proteins. Plant Cell (2011) 1.22
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther (2005) 1.20
JMJ14 is an H3K4 demethylase regulating flowering time in Arabidopsis. Cell Res (2010) 1.17
Human rhinovirus C infections mirror those of human rhinovirus A in children with community-acquired pneumonia. J Clin Virol (2010) 1.16
Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther (2004) 1.14
The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause (2009) 1.13
ABI4 regulates primary seed dormancy by regulating the biogenesis of abscisic acid and gibberellins in arabidopsis. PLoS Genet (2013) 1.13
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
WU and KI polyomavirus present in the respiratory tract of children, but not in immunocompetent adults. J Clin Virol (2008) 1.12
The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine (2006) 1.11
In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol (2008) 1.09